No Data
Yifang Biotech\'s 2025 First Quarter Report
Summary of Yifang Biotech\'s 2024 Annual Report
Yifang Biotech 2024 Annual Report
Are Investors Undervaluing InventisBio Co., Limited (SHSE:688382) By 38%?
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Yifang Bio (688382.SH): Shareholder ABA-Bio intends to reduce its Shareholding by no more than 1.60%.
On April 2, Gelonghui reported that Yi Fang Biotechnology (688382.SH) announced that the shareholder ABA-Bio has issued a notice regarding the shareholder Shareholding plan, proposing to reduce its holdings of the company's shares by a total of no more than 9.23 million shares through centralized bidding and block Trade, with a reduction ratio not exceeding 1.60% of the company's total equity. The Shareholding period is within three months after 15 trading days from the date of this announcement, and the Shareholding price will be determined according to market prices.
